Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Transcend Therapeutics Hits Primary Endpoint in PTSD Study of TSND-201
Details : TSND-201, a rapid-acting neuroplastogen, is a proprietary formulation of methylone. It is being evaluated for PTSD.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 12, 2024
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Use of Methylone in the Treatment of PTSD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Methylone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable